20 stories mentioning INSMUpdated 15h ago
Every FINWIRES story that references INSM, newest first.
Martina Flammer, Chief Medical Officer, on August 06, 2026, sold 27,173 shares in Insmed (INSM) for $3,494,838. Following the Form 4 filing with the SEC, Flammer has control over a total of 60,486 common shares of the company, with 60,486 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000179696026000020/xslF345X05/wk-form4_1786135147.xml
Insmed's (INSM) Q2 results and management commentary reinforced confidence in Brinsupri's commercial performance and pipeline potential, with the stock's rebound appearing appropriate after recent weakness, RBC said in a note Thursday.RBC said Brinsupri generated $309 million in global revenue, beating its $289 million estimate and the Street's $279 million forecast, prompting the company to raise 2026 guidance to between $1.25 billion and $1.4 billion.The brokerage now expects Brinsupri to generate $1.36 billion in 2026 revenue.RBC said TPIP development remains on track across PH-ILD, PAH, PPF and IPF, while the company ended the quarter with $1.16 billion in cash and reiterated its expectation of becoming cash flow positive in 2027.RBC maintained the company's outperform rating and $195 price target.Price: $127.21, Change: $-5.34, Percent Change: -4.03%
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) retreated 0.7% in Thursday's premarket activity as the corporate earnings deluge continues.US stock futures were mixed, with S&P 500 Index futures up 0.01%, Dow Jones Industrial Average futures gaining 0.2%, and Nasdaq futures slipping 0.3% before the start of regular trading.Challenger, Gray & Christmas reported earlier Thursday that layoff intentions declined in July from both June and the previous month, but the technology sector still led the total and artificial intelligence was the key reason listed for the fifth straight month.The weekly jobless claims bulletin showed 199,000 new unemployment claims for the week ended Aug. 1, compared with the upwardly revised figure of 198,000 in the prior week, and it came in above the 205,000 expected, according to estimates compiled by Bloomberg.Q2 nonfarm productivity increased at a 1.4% annual rate, above forecasts for 0.6%, while unit labor costs increased 1.3%, compared with the 2.1% rise expected.Wholesale inventories data for June are due to be released at 10 am ET, followed by weekly natural gas stocks at 10:30 am ET.Federal Reserve St. Louis President Alberto Musalem is slated to speak on Thursday.In premarket activity, bitcoin was down by 0.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.7% lower, Ether ETF (EETH) retreated 0.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) was inactive, the iShares US Technology ETF (IYW) was 0.5% lower, and the iShares Expanded Tech Sector ETF (IGM) was down 1.4%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was up 0.1%, while the iShares Semiconductor ETF (SOXX) fell by 1%.SiTime (SITM) shares were up more than 27% in premarket activity after the company reported higher Q2 adjusted earnings and revenue.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.7%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) gained 0.1%. The iShares Biotechnology ETF (IBB) was 0.5% higher.Insmed (INSM) stock was up more than 26% premarket after the company reported higher Q2 revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) was inactive, and the iShares US Industrials ETF (IYJ) was up 0.3%.LegalZoom (LZ) stock was down 26% after the company cut its fiscal 2026 revenue guidance and announced a 13% companywide workforce reduction.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.6%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.7%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.6% lower.Fiserv (FISV) shares were down 12% in early hours activity after the company reported lower Q2 adjusted earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.2%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 1.6% and the iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) and the VanEck Retail ETF (RTH) were flat, while the State Street SPDR S&P Retail ETF (XRT) was 0.4% higher.Diageo (DEO) shares were up more than 4% pre-bell after the company reported higher fiscal 2026 preliminary adjusted earnings.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.4%.ConocoPhillips (COP) stock was up more than 2% before market open after the company said that Chief Financial Officer Andy O'Brien will succeed Ryan Lance as president and chief executive officer, effective Sept. 1.CommoditiesFront-month US West Texas Intermediate crude oil gained by 1.5% to reach $76.35 per barrel on the New York Mercantile Exchange. Natural gas was down 1.3% at $2.65 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 1.4%, while the United States Natural Gas Fund (UNG) was 0.2% lower.Gold futures for November advanced by 0.6% to $4,329.00 an ounce on the Comex. Silver futures lost 0.5% to reach $61.97 an ounce. SPDR Gold Shares (GLD) was up by 3%, and the iShares Silver Trust (SLV) was 4.4% higher.
Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) was 1% higher and the iShares Biotechnology ETF (IBB) up 0.6%.Insmed (INSM) stock was up more than 28% after the company posted a narrower Q2 loss, as revenue increased during the period, and raised its Brinsupri revenue guidance for 2026.Roivant Sciences (ROIV) shares were down more than 3% after the company reported a decline in fiscal Q1 revenue.Zoetis (ZTS) stock was up more than 1% after the company posted higher Q2 adjusted earnings.
Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.9% and the iShares Biotechnology ETF (IBB) up 0.8%.Insmed (INSM) was up more than 28% after the company posted a narrower Q2 loss, as revenue increased during the period, and raised its Brinsupri revenue guidance for 2026.
Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) and iShares Biotechnology ETF (IBB) up 0.8%.Insmed (INSM) stock was up more than 28% after the company posted a narrower Q2 loss, as revenue increased during the period, and raised its Brinsupri revenue guidance for 2026.
Insmed (INSM) reported a Q2 loss Thursday of $0.06 per share, narrowing from a loss of $1.70 a year earlier.Analysts polled by FactSet expected a loss of $0.69.Revenue for the quarter ended June 30 was $425.5 million, up from $107.4 million a year earlier.An analyst polled by FactSet expected $425.5 million.For 2026, Insmed raised its Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million.Insmed shares were over 21% higher in premarket activity Thursday.Price: $120.60, Change: $+21.58, Percent Change: +21.79%
William Lewis, Director, Chair, and CEO, on July 23, 2026, sold 10,700 shares in Insmed (INSM) for $1,134,890. Following the Form 4 filing with the SEC, Lewis has control over a total of 492,982 common shares of the company, with 259,058 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000042/xslF345X05/wk-form4_1784926946.xml
Insmed (INSM) has an average rating of buy and mean price target of $196.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
William Lewis, Director, Chair and CEO, on July 09, 2026, sold 10,699 shares in Insmed (INSM) for $1,256,084. Following the Form 4 filing with the SEC, Lewis has control over a total of 492,982 common shares of the company, with 259,058 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000040/xslF345X05/wk-form4_1783713769.xml
Martina Flammer, Chief Medical Officer, on July 06, 2026, sold 12,302 shares in Insmed (INSM) for $1,352,932. Following the Form 4 filing with the SEC, Flammer has control over a total of 60,486 common shares of the company, with 60,486 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000179696026000018/xslF345X05/wk-form4_1783541018.xml
William Lewis, Director, Chair and CEO, on June 25, 2026, sold 21,398 shares in Insmed (INSM) for $2,210,763. Following the Form 4 filing with the SEC, Lewis has control over a total of 492,841 common shares of the company, with 258,917 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000038/xslF345X05/wk-form4_1782504217.xml
US equity indexes were lower on Friday amid a sell-off in mega-cap tech stocks following a stronger-than-expected jobs report.* Nonfarm payrolls surged by 172,000 in May, above the 88,000 jobs increase expected in a Bloomberg-compiled survey. April was revised upwards to a 179,000 increase, and March payrolls were revised upwards to a 214,000 increase, the Bureau of Labor Statistics said Friday.* The probability of a 25 basis-point increase in interest rates in December surged to 43%, from 36% a week ago, according to the CME FedWatch tool.* July West Texas Intermediate crude oil fell $2.76 to settle at $90.28 per barrel, while August Brent crude, the global benchmark, was last seen down $2.12 at $92.91.* Cooper (COO) shares were up about 8.6%, the top gainer on S&P 500, after the company reported stronger-than-expected growth in fiscal Q2 adjusted earnings and sales.* Insmed (INSM) shares were down roughly 10%, among the steepest decliners on the Nasdaq, after RBC Capital Markets said Friday that brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug.
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) declined 1.8%.In corporate news, Insmed (INSM) brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug, RBC Capital Markets said Friday. Insmed shares were down 11%.
Insmed (INSM) brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug, RBC Capital Markets said in a Friday note.The brokerage said its key opinion leader has depicted a strong growth opportunity for brensocatib, marketed as Brinsupri, in his practice based on its compelling efficacy with no new exacerbations observed to date in his experience, strong safety with no discontinuations in more than 60 patients and only a single dose reduction, and a generally permissive payer environment, albeit with some pockets of stringency such as the VA system.The KOL mentioned that patient enthusiasm for Brinsupri is notably high with many patients already having heard about the drug through support groups, RBC said, adding that compliance is strong, attributed to it being a once-daily oral pill relative to more burdensome existing regimens.The investment firm added that it continues to see upside to the company's $1 billion sales estimate for the drug in 2026.RBC lowered its price target to $195 from $205 and maintained its outperform rating.Shares of Insmed were down more than 7.7% in Friday trading.Price: $96.90, Change: $-8.03, Percent Change: -7.65%
Michael Alexander Smith, Chief Legal Officer, on May 22, 2026, sold 6,149 shares in Insmed (INSM) for $666,982. Following the Form 4 filing with the SEC, Smith has control over a total of 41,613 common shares of the company, with 41,613 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000187027826000015/xslF345X05/wk-form4_1779481519.xml
Insmed (INSM) stock sell-off post Q1 results is overdone as underlying metrics appear positive and potential organic patient additions throughout the year should enable Brinsupri for non-cystic fibrosis bronchiectasis to clear the $1 billion floor with cushion, RBC Capital Markets said in a research note emailed Friday.The stock reaction could be due to investor concerns about a slump in patient additions and compliance, but the brokerage said it maintained its full-year 2026 Brinsupri sales guidance of around $1.3 billion.RBC concurs with Insmed's view that opportunity to ramp patient count through "doc experience" with Brinsupri could be considerable, while the pulmonary community presents an opportunity for future tailwinds as the company focuses on marketing and diagnostics, according to the note.There will be a balance between compliance creeping down, tightening of approval rates, future competitors, and the pool of latent patients that can be activated, which could drive $8 billion in US peak sales, analysts wrote.The brokerage said it reiterated its outperform rating on the stock and cut its price target to $205 per share from $220.Price: $99.51, Change: $-5.29, Percent Change: -5.05%
Insmed (INSM) has an average rating of buy and mean price target of $212.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $100.81, Change: $-4.00, Percent Change: -3.81%
William Lewis, Director, Chair and CEO, on May 04, 2026, sold 10,699 shares in Insmed (INSM) for $1,469,442. Following the Form 4 filing with the SEC, Lewis has control over a total of 535,109 common shares of the company, with 301,185 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000026/xslF345X05/wk-form4_1778098286.xml
Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.Price: $152.47, Change: $+1.33, Percent Change: +0.88%
